Zobrazeno 1 - 10
of 14 087
pro vyhledávání: ''
Autor:
Lorinda Simms, Shehkar Patil, David R. Gandara, Anders Mellemgaard, Raghunadharao Digumarti, Bonne Biesma, Johan Vansteenkiste, Mauro Zukin, Joachim von Pawel, Katherine P. Sugarman, Keunchil Park, Christian Manegold, Filippo de Marinis, Tuncay Göksel, Janusz Rolski, Piotr Serwatowski, Jin S. Lee, Giorgio V. Scagliotti, Ulrich Gatzemeier, Purvish M. Parikh
Publikováno v:
Journal of Clinical Oncology. 41:2458-2466
PURPOSE Cisplatin plus gemcitabine is a standard regimen for first-line treatment of advanced non–small-cell lung cancer (NSCLC). Phase II studies of pemetrexed plus platinum compounds have also shown activity in this setting. PATIENTS AND METHODS
Autor:
Ulrich Gatzemeier, Michael Boyer, Paolo Paoletti, Salih Emri, Christian Manegold, Claude Denham, Nicholas J. Vogelzang, James J. Rusthoven, James T. Symanowski, Clet Niyikiza, E. Kaukel, Pierre Ruffié
Publikováno v:
Journal of Clinical Oncology. 41:2125-2133
PURPOSE Patients with malignant pleural mesothelioma, a rapidly progressing malignancy with a median survival time of 6 to 9 months, have previously responded poorly to chemotherapy. We conducted a phase III trial to determine whether treatment with
Autor:
Ashish Panigrahi, Constantine S. Tam, Piers Blombery, Xiangting Chen, John F. Seymour, Dennis A. Carney, Andrew H. Wei, Thomas E Lew, Mary Ann Anderson, Andrew W. Roberts, Ella R. Thompson, David C. S. Huang, Tamia Nguyen, David Westerman, Michael A. Dengler, Victor S Lin, Sasanka M. Handunnetti, Jerry M. Adams
Publikováno v:
Blood. 139:1198-1207
The BCL2 inhibitor venetoclax has established therapeutic roles in chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). As BCL2 is an important determinant of survival of both myeloid progenitor and B cells, we investigated whether cl
Autor:
Bhumsuk Keam, Keon Uk Park, Hye Ryun Kim, Keun-Wook Lee, Sung-Bae Kim, Seong Hoon Shin, Jin-Hyuk Choi, Eun Joo Kang, Yun-Gyoo Lee, Hyo Jung Kim, Min Kyoung Kim, Hwan Jung Yun, Kyoung Eun Lee, Jin-Soo Kim, Hee Kyung Ahn
Publikováno v:
Cancer Research and Treatment : Official Journal of Korean Cancer Association
Purpose Certain patient subgroups who do not respond to induction chemotherapy (IC) show inherent chemoresistance in locally advanced head and neck squamous cell carcinoma (LA-HNSCC). This study aimed to assess the prognostic value of IC, and role of
Autor:
Guofan Xu, Lei Feng, Hun Ju Lee, Michelle Avellaneda, Preetesh Jain, Linghua Wang, Luis Fayad, Omar Moghrabi, L. Jeffrey Medeiros, Cezar Iliescu, Nathan Fowler, Shuangtao Zhao, Yang Liu, Selvi Thirumurthi, Michael L. Wang, Chi Young Ok, Maria Badillo, Lucy Navsaria, Graciela M. Nogueras González, David Santos, Christopher R. Flowers, Francisco Vega, Guilin Tang, Holly Hill, Rashmi Kanagal-Shamanna, Fredrick B. Hagemeister, Yixin Yao
Publikováno v:
J Clin Oncol
PURPOSE Most patients with mantle cell lymphoma (MCL) are older. In this study, we investigated the efficacy and safety of a chemotherapy-free combination with ibrutinib and rituximab (IR) in previously untreated older patients with MCL (age ≥ 65 y
Autor:
Diogo Assed Bastos, Juan Carlos Vazquez Limon, Lisa G. Horvath, Héctor Manuel Sánchez López, J.N. Minatta, Daniel Castellano, Margitta Retz, Jia Li, Fred Saad, Daniel P. Petrylak, Neha P. Amin, David R. Shaffer, Arash Rezazadeh Kalebasty, Keziban Unsal-Kacmaz, Andrew J. Armstrong, Russell K. Pachynski, Karim Fizazi, Pablo González Mella
Publikováno v:
European Journal of Cancer. 160:61-71
Background Docetaxel has immunostimulatory effects that may promote an immunoresponsive prostate tumour microenvironment, providing a rationale for combination with nivolumab (programmed death-1 inhibitor) for metastatic castration-resistant prostate
Autor:
Ariadna Juarez-Garcia, John C O'Donnell, John R. Penrod, Mats Rosenlund, Simon Ekman, Jens Benn Sørensen, Anne Mette Kejs, Pia Horvat, L. Lacoin, Odd Terje Brustugun, Dony Patel, M. Daumont
Publikováno v:
Sørensen, J B, Horvat, P, Rosenlund, M, Kejs, A M, Patel, D, Juarez-Garcia, A, Lacoin, L, Daumont, M J, Penrod, J R, O'donnell, J C, Brustugun, O T & Ekman, S 2022, ' Initial treatment and survival in Danish patients diagnosed with non-small-cell lung cancer (2005-2015) : SCAN-LEAF study ', Future Oncology, vol. 18, no. 2, pp. 205-214 . https://doi.org/10.2217/fon-2021-0746
Aim: To describe initial treatment patterns and survival of patients diagnosed with non-small-cell lung cancer (NSCLC) in Denmark, before immune checkpoint inhibitor and later-generation tyrosine kinase inhibitor use. Patients & methods: Adults diagn
Autor:
Scott J. Diede, Michele Del Vecchio, Pier Francesco Ferrucci, Razi Ghori, Wilson H. Miller, Omid Hamid, Paolo A. Ascierto, Marcus O. Butler, Matteo S. Carlino, Antoni Ribas, Eduard Gasal, Elaine McWhirter, Robert Zielinski, Elizabeth Croydon, Michele Maio, Anthony M. Joshua
Publikováno v:
European Journal of Cancer. 160:1-11
OBJECTIVES Parts 4 and 5 of the phase 1/2 KEYNOTE-022 study investigated the maximum tolerated dose (MTD), safety, and efficacy of pembrolizumab plus trametinib in solid tumours and BRAF wild-type melanoma. PATIENTS AND METHODS Patients received inte
Autor:
Fritz Offner, Karima Amaador, Kazem Nasserinejad, Dries Deeren, Efstathios Kastritis, Steven T. Pals, Willem Kraan, Jeanette K. Doorduijn, Roberto D Liu, Monique C. Minnema, Marcel Kap, Marie José Kersten, Lara H Böhmer, Lidwine W. Tick, Meletios A. Dimopoulos, Josephine M.I. Vos, Martine E D Chamuleau, Maria Gavriatopoulou
Publikováno v:
JOURNAL OF CLINICAL ONCOLOGY
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 40(1), 40-51. American Society of Clinical Oncology
Kersten, M J, Amaador, K, Minnema, M C, Vos, J M I, Nasserinejad, K, Kap, M, Kastritis, E, Gavriatopoulou, M, Kraan, W, Chamuleau, M E D, Deeren, D, Tick, L W, Doorduijn, J K, Offner, F, Böhmer, L H, Liu, R D, Pals, S T & Dimopoulos, M A 2022, ' Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia : Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 40, no. 1, pp. 40-51 . https://doi.org/10.1200/JCO.21.00105
Journal of clinical oncology, 40(1), 40-51. American Society of Clinical Oncology
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 40(1), 40-51. American Society of Clinical Oncology
Kersten, M J, Amaador, K, Minnema, M C, Vos, J M I, Nasserinejad, K, Kap, M, Kastritis, E, Gavriatopoulou, M, Kraan, W, Chamuleau, M E D, Deeren, D, Tick, L W, Doorduijn, J K, Offner, F, Böhmer, L H, Liu, R D, Pals, S T & Dimopoulos, M A 2022, ' Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia : Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 40, no. 1, pp. 40-51 . https://doi.org/10.1200/JCO.21.00105
Journal of clinical oncology, 40(1), 40-51. American Society of Clinical Oncology
PURPOSE Proteasome inhibitors are effective in Waldenström's macroglobulinemia (WM) but require parenteral administration and are associated with polyneuropathy. We investigated efficacy and toxicity of the less neurotoxic oral proteasome inhibitor
Autor:
Nicolas Girard, Gaëtane Simon, Maurice Pérol, Thomas Filleron, Christos Chouaid, Roland Schott, Matthieu Carton, Clarisse Audigier Valette, Mathieu Robain, Xavier Quantin, Didier Debieuvre, Radj Gervais, Hervé Lena, Bruno Coudert
Publikováno v:
Lung Cancer. 162:119-127
Background Cisplatin-based chemotherapy administered concurrently to thoracic radiation therapy is the recommended treatment for fit patients with unresectable stage III NSCLC. The aim of this study was to describe patient profiles and clinical outco